Mudanças entre as edições de "As CD29, CD44, CD55, CD59, and CD73, but not for CD"

De ABEC Wiki
Ir para: navegação, pesquisa
m (As CD29, CD44, CD55, CD59, and CD73, but not for CD)
m (As CD29, CD44, CD55, CD59, and CD73, but not for CD)
 
Linha 1: Linha 1:
Journal of Experimental  Clinical Cancer Analysis 2010, 29:163 http://www.jeccr.com/content/29/1/Page two ofcommon precursors of both MSCs and hematopoietic stem cells (HSCs). HPB-AML-I has been regarded a exclusive cell line. In spite of its establishment in the peripheral blood mononuclear cells (PBMCs) of a case with acute myeloid leukemia (AML)-M1, this cell line reportedly ha.As CD29, CD44, CD55, CD59, and CD73, but not for CD14, CD19, CD34, CD45, CD90, CD105, CD117, and HLA-DR. Karyotypic analysis showed the presence of complex abnormalities, but no reciprocal translocations normally detected in AML situations. Following the induction of differentiation toward adipocytes, chondrocytes, and osteocytes, HPB-AML-I cells showed, in conjunction with extracellular matrix formation, lipid accumulation, proteoglycan synthesis, and alkaline phosphatase expression. Mixed lymphocyte culture demonstrated that CD3+ T-cell proliferation was suppressed in the presence of HPB-AML-I cells. Conclusions: We conclude that HPB-AML-I cells seem to become distinctive neoplastic cells, which could be derived from MSCs, but are certainly not hematopoietic progenitor cells.Background Mesenchymal stem cells (MSCs) constitute a cell population, which attributes self-renewal and differentiation into adipocytes, chondrocytes, and osteocytes. Human MSCs happen to be isolated from a variety of tissues and organs, which include muscle, cartilage, synovium, dental pulp, bone marrow, tonsils, adipose tissues, placenta, umbilical cord, and thymus (reviewed by [1]). The biological roles of MSCs were initially described by Friedenstein and colleagues in 1970s. They observed bone formation and reconstitution on the hematopoietic microenvironment in rodents with subcutaneously transplanted MSCs (reviewed by [2]). In* Correspondence: bambang.ardianto@gmail.com; sjkawano@med.kobe-u.ac.jp 1 Division of Molecular Medicine and Medical Genetics, Department of Pathology, Graduate College of Medicine, Kobe University, Kobe, Japan two Division of Clinical Pathology and Immunology, Graduate School of Medicine, Kobe University, Chuo-Ku, Kobe 650-0017, Japan Full list of author details is accessible at the finish from the articleaddition to offering assistance for the early stage of hematopoiesis, MSCs have also been reported to suppress the proliferation of CD3+ T-cells [3], which led for the utilization of MSCs within the management of various pathologic circumstances, which include graft-versus-host illness (GvHD) immediately after allogeneic bone marrow transplantation (reviewed by [4-6]). Current studies have effectively isolated cancer-initiating cells with properties similar to these of MSCs from [http://cswygwzj.com/comment/html/?355491.html Ack to Nterminal residues as well as to coils within the] situations with some neoplasms, including osteosarcoma [7], Ewing's sarcoma [8], and chondrosarcoma [9]. Moreover, the qualities of MSCs isolated from situations with hematopoietic neoplasms have also been investigated. Shalapour et al. [10] and Menendez et al. [11] identified the presence of oncogenic fusion transcripts, for example TEL-AML1, E2A-PBX1, and MLL rearrangements, in MSCs isolated [https://www.ncbi.nlm.nih.gov/pubmed/21795619 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/21795619] from situations with B-lineage acute lymphoblastic leukemia (B-ALL). These reports suggested that some leukemias might be derived in the?2010 Ardianto et al; licensee BioMed Central Ltd. This can be an Open Access report distributed beneath the terms with the Inventive Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction [https://www.ncbi.nlm.nih.gov/pubmed/24247322 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/24247322] in any medium, provided the original function is effectively cited.Ardianto et al.
+
Journal of Experimental  Clinical Cancer Study 2010, 29:163 http://www.jeccr.com/content/29/1/Page two ofcommon precursors of both MSCs and hematopoietic stem cells (HSCs). HPB-AML-I has been considered a exceptional cell line. In spite of its establishment from the peripheral blood mononuclear cells (PBMCs) of a case with acute myeloid leukemia (AML)-M1, this cell line reportedly ha.As CD29, CD44, CD55, CD59, and CD73, but not for CD14, CD19, CD34, CD45, CD90, CD105, CD117, and HLA-DR. Karyotypic analysis showed the presence of complex abnormalities, but no reciprocal translocations typically detected in AML cases. Following the induction of differentiation toward adipocytes, chondrocytes, and osteocytes, HPB-AML-I cells showed, in conjunction with extracellular matrix formation, lipid accumulation, proteoglycan synthesis, and alkaline phosphatase expression. Mixed lymphocyte culture demonstrated that CD3+ T-cell proliferation was suppressed within the presence of HPB-AML-I cells. Conclusions: We conclude that HPB-AML-I cells seem to be distinctive neoplastic cells, which may be derived from MSCs, but are certainly not hematopoietic progenitor cells.Background Mesenchymal stem cells (MSCs) constitute a cell population, which functions self-renewal and differentiation into adipocytes, chondrocytes, and osteocytes. Human MSCs have already been isolated from several tissues and organs, like muscle, cartilage, synovium, dental pulp, bone marrow, tonsils, adipose tissues, placenta, umbilical cord, and thymus (reviewed by [1]). The biological roles of MSCs have been initially described by Friedenstein and colleagues in 1970s. They observed bone formation and reconstitution from the hematopoietic microenvironment in rodents with subcutaneously transplanted MSCs (reviewed by [2]). In* Correspondence: bambang.ardianto@gmail.com; sjkawano@med.kobe-u.ac.jp 1 Division of Molecular Medicine and Health-related Genetics, Department of Pathology, Graduate College of Medicine, Kobe University, Kobe, Japan 2 Department of Clinical Pathology and Immunology, Graduate School of Medicine, Kobe University, Chuo-Ku, Kobe 650-0017, Japan Complete list of author details is out there at the finish on the articleaddition to offering help for the early stage of hematopoiesis, MSCs have also been reported to suppress the proliferation of CD3+ T-cells [3], which led to the utilization of MSCs within the management of several pathologic circumstances, for instance graft-versus-host disease (GvHD) after allogeneic bone marrow transplantation (reviewed by [4-6]). Current [http://www.dogful.com/streams/p/611464/ Ons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies] research have successfully isolated cancer-initiating cells with properties equivalent to these of MSCs from situations with some neoplasms, for instance osteosarcoma [7], Ewing's sarcoma [8], and chondrosarcoma [9]. Moreover, the traits of MSCs isolated from circumstances with hematopoietic neoplasms have also been investigated. Shalapour et al. [10] and Menendez et al. [11] identified the presence of oncogenic fusion transcripts, for example TEL-AML1, E2A-PBX1, and MLL rearrangements, in MSCs isolated [https://www.ncbi.nlm.nih.gov/pubmed/21795619 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/21795619] from circumstances with B-lineage acute lymphoblastic leukemia (B-ALL). These reports suggested that some leukemias might be derived from the?2010 Ardianto et al; licensee BioMed Central Ltd. That is an Open Access article distributed under the terms in the Inventive Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction [https://www.ncbi.nlm.nih.gov/pubmed/24247322 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/24247322] in any medium, supplied the original function is adequately cited.Ardianto et al.

Edição atual tal como às 05h39min de 10 de julho de 2018

Journal of Experimental Clinical Cancer Study 2010, 29:163 http://www.jeccr.com/content/29/1/Page two ofcommon precursors of both MSCs and hematopoietic stem cells (HSCs). HPB-AML-I has been considered a exceptional cell line. In spite of its establishment from the peripheral blood mononuclear cells (PBMCs) of a case with acute myeloid leukemia (AML)-M1, this cell line reportedly ha.As CD29, CD44, CD55, CD59, and CD73, but not for CD14, CD19, CD34, CD45, CD90, CD105, CD117, and HLA-DR. Karyotypic analysis showed the presence of complex abnormalities, but no reciprocal translocations typically detected in AML cases. Following the induction of differentiation toward adipocytes, chondrocytes, and osteocytes, HPB-AML-I cells showed, in conjunction with extracellular matrix formation, lipid accumulation, proteoglycan synthesis, and alkaline phosphatase expression. Mixed lymphocyte culture demonstrated that CD3+ T-cell proliferation was suppressed within the presence of HPB-AML-I cells. Conclusions: We conclude that HPB-AML-I cells seem to be distinctive neoplastic cells, which may be derived from MSCs, but are certainly not hematopoietic progenitor cells.Background Mesenchymal stem cells (MSCs) constitute a cell population, which functions self-renewal and differentiation into adipocytes, chondrocytes, and osteocytes. Human MSCs have already been isolated from several tissues and organs, like muscle, cartilage, synovium, dental pulp, bone marrow, tonsils, adipose tissues, placenta, umbilical cord, and thymus (reviewed by [1]). The biological roles of MSCs have been initially described by Friedenstein and colleagues in 1970s. They observed bone formation and reconstitution from the hematopoietic microenvironment in rodents with subcutaneously transplanted MSCs (reviewed by [2]). In* Correspondence: bambang.ardianto@gmail.com; sjkawano@med.kobe-u.ac.jp 1 Division of Molecular Medicine and Health-related Genetics, Department of Pathology, Graduate College of Medicine, Kobe University, Kobe, Japan 2 Department of Clinical Pathology and Immunology, Graduate School of Medicine, Kobe University, Chuo-Ku, Kobe 650-0017, Japan Complete list of author details is out there at the finish on the articleaddition to offering help for the early stage of hematopoiesis, MSCs have also been reported to suppress the proliferation of CD3+ T-cells [3], which led to the utilization of MSCs within the management of several pathologic circumstances, for instance graft-versus-host disease (GvHD) after allogeneic bone marrow transplantation (reviewed by [4-6]). Current Ons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies research have successfully isolated cancer-initiating cells with properties equivalent to these of MSCs from situations with some neoplasms, for instance osteosarcoma [7], Ewing's sarcoma [8], and chondrosarcoma [9]. Moreover, the traits of MSCs isolated from circumstances with hematopoietic neoplasms have also been investigated. Shalapour et al. [10] and Menendez et al. [11] identified the presence of oncogenic fusion transcripts, for example TEL-AML1, E2A-PBX1, and MLL rearrangements, in MSCs isolated PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/21795619 from circumstances with B-lineage acute lymphoblastic leukemia (B-ALL). These reports suggested that some leukemias might be derived from the?2010 Ardianto et al; licensee BioMed Central Ltd. That is an Open Access article distributed under the terms in the Inventive Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/24247322 in any medium, supplied the original function is adequately cited.Ardianto et al.